Linked Life Data

1283848

Source:http://linkedlifedata.com/resource/pubmed/id/1283848

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1993-3-23
pubmed:abstractText
The use of vinorelbine 30 mg/m2/week as a single-agent treatment in advanced breast cancer has achieved response rates of > 20% as second-line treatment and 40 to 50% as first-line treatment. The major toxicity of the drug is reversible neutropenia; 35 to 50% of treated patients have grade IV neutropenia. The agent did not induce thrombocytopenia and proved mildly emetogenic and neurotoxic. Activity was confirmed in combination with fluorouracil or doxorubicin, when response rates ranging from 60 to 74% were achieved. Thus, vinorelbine appears to be a promising agent in the treatment of advanced breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0012-6667
pubmed:author
pubmed:issnType
Print
pubmed:volume
44 Suppl 4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
29-35; discussion 66-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
A review of the antitumour activity of vinorelbine in breast cancer.
pubmed:affiliation
Department of Medical Oncology, Hôpital Saint Louis, Paris, France.
pubmed:publicationType
Journal Article, Clinical Trial, In Vitro, Review, Multicenter Study